Advanced search
Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Email Registration
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. Financials
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
Delayed Nasdaq  -  04:00:00 2023-06-01 pm EDT
104.12 USD   -0.91%
06:46aBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
GL
06:45aBioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
AQ
06/01HC Wainwright Cuts Price Target on BioNTech to $181 From $198, Maintains Buy Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization1 16 07154 76434 11223 371--
Enterprise Value (EV)1 14 96453 37220 4495 3024 4784 323
P/E ratio 1 112x5,72x3,72x19,9x27,2x46,4x
Yield ------
Capitalization / Revenue 33,3x2,89x1,97x4,21x4,90x5,48x
EV / Revenue 31,0x2,81x1,18x0,96x0,94x1,01x
EV / EBITDA -343x3,47x1,60x3,08x4,36x6,82x
Enterprise Value (EV) / FCF -188x72,5x1,55x0,97x3,53x7,29x
FCF Yield -0,53%1,38%64,6%103%28,3%13,7%
Price to Book 11,8x4,62x-1,13x1,10x1,11x
Nbr of stocks (in thousands) 240 786241 521243 019240 990--
Reference price (EUR) 66,722714097,097,097,0
Announcement Date 03/30/202103/30/202203/27/2023---
1 EUR in Million
Previous periodNext period
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales1 48218 97717 3115 5454 7734 262
EBITDA1 -43,715 35912 7661 7201 028634
Operating profit (EBIT)1 -82,415 28412 6431 450950547
Operating Margin -17,1%80,5%73,0%26,1%19,9%12,8%
Pre-Tax Profit (EBT)1 -14615 04612 9541 7181 3931 249
Net income1 15,210 2939 4341 251911617
Net margin 3,15%54,2%54,5%22,6%19,1%14,5%
EPS2 0,0639,637,84,883,572,09
Free Cash Flow1 -79,573613 2145 4421 267593
FCF margin -16,5%3,88%76,3%98,1%26,6%13,9%
FCF Conversion 182%4,79%104%316%123%93,5%
Dividend per Share2 ------
Announcement Date 03/30/202103/30/202203/27/2023---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4
Net sales1 3 4614 2781 2776171 5412 069
EBITDA1 2 4213 322686-2971 429570
Operating profit (EBIT)1 2 3883 293654-52,6442511
Operating Margin 69,0%77,0%51,2%-8,52%28,7%24,7%
Pre-Tax Profit (EBT)1 2 4443 173708378392245
Net income1 1 7852 279502-63,0420522
Net margin 51,6%53,3%39,3%-10,2%27,2%25,2%
EPS2 6,989,262,05-0,501,242,41
Dividend per Share2 ------
Announcement Date 11/07/202203/27/202305/08/2023---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Balance Sheet Analysis
Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt1 ------
Net Cash position1 1 1071 39113 66318 06918 89319 047
Leverage (Debt / EBITDA) 25,4x-0,09x-1,07x-10,5x-18,4x-30,0x
Free Cash Flow1 -79,573613 2145 4421 267593
ROE (Net Profit / Equities) 1,63%155%59,1%5,87%2,04%1,04%
Shareholders' equity1 9336 63315 97521 32444 59459 532
ROA (Net Profit / Asset) 0,98%113%48,2%5,86%3,62%1,71%
Assets1 1 5589 07519 55521 34725 18836 150
Book Value Per Share2 5,6849,0-85,588,487,5
Cash Flow per Share2 -0,053,4355,819,33,194,69
Capex1 66,0128329483353335
Capex / Sales 13,7%0,67%1,90%8,71%7,40%7,86%
Announcement Date 03/30/202103/30/202203/27/2023---
1 EUR in Million
2 EUR
Previous periodNext period
Estimates
Analysis
Moderna cancer vaccine with Merck's Keytruda delays return of deadly skin cancer
Key data
Capitalization (USD) 25 091 930 755
Net sales (EUR) 17 310 600 000
Net sales (USD) 18 585 570 110
Number of employees 5 100
Sales / Employee (EUR) 3 394 235
Sales / Employee (USD) 3 644 229
Free-Float 86,5%
Free-Float capitalization (USD) 21 699 630 577
Avg. Exchange 20 sessions (EUR) 100 366 359
Avg. Exchange 20 sessions (USD) 107 758 599
Average Daily Capital Traded 0,40%
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1 MarketScreener is worth more than 1000 Influencers!
100% Free Registration
fermer